PIKA COVID-19 vaccine is currently in Phase 3, multi-country, multi-center clinical trial conducted at Southeast Asian and Middle East countries.
The acquisition is for an enterprise value of Rs. 218 crores
Revenue is up 23% whereas Profit After Tax expands 29% for the company
According to IQVIA sales data for the 12-month period ending September 2022, the Gilenya Capsules, 0.5 mg market achieved annual sales of approximately US $1.8 billion
The voluntary program is the first time the FDA will allow excipient manufacturers to obtain review of certain novel excipients prior to their use in drug formulations.
The expansion program includes investments in France and the U.S., adding an additional 23,000+ m² of manufacturing footprint.
This is the first injectable product approval from our General Sterile Facility (F-3) which was inspected in August, 2022.
Gland Pharma Q2 FY2023 consolidated net profit up at Rs. 241.24 Cr
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
Subscribe To Our Newsletter & Stay Updated
